- Daklinza is an NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 1 or 3 infection.
AND
AND
AND
AND
AND
AND
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
Zepatier | Genotype 1a: | 12 weeks |
Zepatier | Genotype 1b: | 12 weeks |
Zepatier + ribavirin | Genotype 1a: | 16 weeks |
Zepatier + ribavirin | Genotype 1a or 1b: | 12 weeks |
Epclusa | Genotype 2 and 3: | 12 weeks |
Epclusa + ribavirin | Genotype 2 and 3: | 12 weeks |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Daklinza, Sovaldi | GT1 treatment naive or treatment experienced with Peg-IFN/RBV with or without protease inhibitor, and without cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT1 treatment naive or treatment experienced with Peg-IFN/RBV with or without protease inhibitor, and with cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with or without weight based RBV | 24 weeks |
Daklinza, Sovaldi | GT1 with decompensated cirrhosis (including those with hepatocellular carcinoma): Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 12 weeks |
Daklinza, Sovaldi | GT1 with decompensated cirrhosis (including those with hepatocellular carcinoma) and intolerant to RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza, Sovaldi | GT2, treatment naive without cirrhosis, AND, unable to tolerate RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT2 who are not eligible to receive IFN, in whom previous treatment with Sovaldi/RBV has failed: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with or without RBV | 24 weeks |
Daklinza, Sovaldi | GT3, treatment naive or treatment experienced with Peg IFN/RBV without cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT 3, treatment naive or treatment experienced with Peg IFN/RBV with cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza, Sovaldi | GT 3 who are not eligible to receive IFN, in whom previous treatment with Sovaldi/RBV has failed: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 24 weeks |
Daklinza, Sovaldi | GT 1, 2 or 3 infection in the allograft, including those with compensated cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 12 weeks |
Daklinza, Sovaldi | GT 1, 2 or 3 infection in the allograft, including those with compensated cirrhosis and intolerant to RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza dose modification | Reduce dosage to 30 mg PO QD with strong CYP3A4 inhibitors and increase to 90 mg PO QD with moderate CYP3A inducers. | This field intentionally left blank |